<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528359</url>
  </required_header>
  <id_info>
    <org_study_id>AAD-001</org_study_id>
    <nct_id>NCT00528359</nct_id>
  </id_info>
  <brief_title>β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS</brief_title>
  <acronym>SANAT</acronym>
  <official_title>Phase 1 Study of Insulin Sensitivity, Adjusted β-Cell Function and Adiponectin Among Lean Drug-naïve Schizophrenic Subjects Treated With Atypical Antipsychotic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether atypical antipsychotic drugs (commonly
      prescribed for treating schizophrenia) induce changes in anthropometry and metabolism,
      including alteration in insulin sensitivity and/or insulin secretion by the pancreas, when
      given to lean, non-diabetic, individuals who are antipsychotic drug(s)-naïve, and free of
      metabolic syndrome at enrollment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atypical antipsychotic drugs (AADs) induce weight gain, truncal adiposity and may engender a
      metabolic syndrome which may progress to IFG/IGT or DM. AADs effects in lean schizophrenic
      patients without metabolic syndrome are not documented, especially the relationship between
      weight gain and changes in insulin sensitivity (S), beta-cell function (β), and circulating
      adiponectin. We prospectively determined the outcome of 9-month therapy with AADs on
      anthropometrics, metabolism and adiponectin, including HOMA-modeling of S, β, and βxS
      (hyperbolic product, assessing individual β adjusted for S)in 36 schizophrenic subjects (M:F
      24:12; Caucasian n=23; North-African n=12; South-Asian n=1) aged 35±9 years (mean±1SD) free
      of MetS (NCEP-ATPIII).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>36 lean schizophrenic subjects free of metabolic syndrome(M:F 24:12; Caucasian n=23; North-African n=12; South-Asian n=1)aged 35±9 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine or olanzapine or risperidone or aripiprazole</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-55 years

          -  body mass index &lt;25.0 kg/m²

          -  waist circumference &lt;102 (men) and &lt;88 cm (women)

          -  absence of a metabolic syndrome according to NCEP ATPIII criteria

          -  normoglycaemic (fasting plasma glucose levels &lt;100 mg/dl)

        Exclusion Criteria:

          -  previous use of antipsychotic drugs

          -  concomitant therapy with drugs known to possess an inherent potential to increase
             weight and/or to alter glucose metabolism (including antihistaminic drugs,
             glucocorticoids, β-blockers, antiepileptic drugs and mirtazapine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe M ORIOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Catholique de Louvain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanatia Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1030</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2007</study_first_submitted>
  <study_first_submitted_qc>September 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2007</study_first_posted>
  <last_update_submitted>March 10, 2008</last_update_submitted>
  <last_update_submitted_qc>March 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2008</last_update_posted>
  <keyword>antipsychotic drugs</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>β-cell function</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

